Faron Pharmaceuticals Oy (LON:FARN) Hits New 52-Week Low – What’s Next?

Faron Pharmaceuticals Oy (LON:FARN) hit a new 52-week low during trading on Monday. The stock traded as low as GBX 28 and last traded at GBX 29.83, with a volume of 64,571 shares trading hands. The stock had previously closed at GBX 29.90.

Faron Pharmaceuticals Oy Price Performance

The firm has a market capitalization of £60.52 million, a PE ratio of -2.59 and a beta of 1.12. The firm’s fifty day moving average price is GBX 35.09 and its 200 day moving average price is GBX 50.86. The company has a current ratio of 2.40, a quick ratio of 1.09 and a debt-to-equity ratio of 154.15.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.